{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:44:13Z","timestamp":1790174653238,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.lpm.2014.03.028","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T13:17:25Z","timestamp":1406207845000},"page":"1056-1066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["Les bioth\u00e9rapies des cancers colorectaux m\u00e9tastatiques en 2014"],"prefix":"10.1016","volume":"43","author":[{"given":"Anne","family":"Jouinot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2014.03.028_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.lpm.2014.03.028_bib0010","series-title":"Colorectal Cancer: a clinical guide to therapy","first-page":"531","article-title":"New Combinations in colorectal cancer","author":"Goldwasser","year":"2002"},{"key":"10.1016\/j.lpm.2014.03.028_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000315730","article-title":"Metastatic colorectal cancer: from improved survival to potential cure","volume":"78","author":"Gallagher","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.lpm.2014.03.028_bib0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lpm.2011.03.020","article-title":"Le traitement du cancer colo-rectal m\u00e9tastatique en 2011\u00a0: une illustration de l\u2019\u00e9volution des concepts fondateurs de la canc\u00e9rologie","volume":"41","author":"Goldwasser","year":"2012","journal-title":"Press Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0025","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0030","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0035","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.03.028_bib0040","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1026535824044","article-title":"Dose escalation of CPT-11\u00a0in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients","volume":"11","author":"Goldwasser","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0045","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3\u00a0trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.03.028_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0060","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2012.385","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2014.03.028_bib0065","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0070","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0075","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0080","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0085","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study","volume":"17","author":"D\u00edaz-Rubio","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.lpm.2014.03.028_bib0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3\u00a0trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0100","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0105","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/annonc\/mdp206","article-title":"Hypertension as a surrogate marker for the activity of anti-VEGF agents","volume":"20","author":"Mir","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0120","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","article-title":"An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity","volume":"16","author":"Mir","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.lpm.2014.03.028_bib0125","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.lpm.2014.03.028_bib0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jnci\/djk011","article-title":"Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrom?","volume":"99","author":"Mir","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lpm.2014.03.028_bib0135","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s10637-010-9500-9","article-title":"VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption","volume":"29","author":"Ropert","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.lpm.2014.03.028_bib0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-011-0201-x","article-title":"Posterior reversible encephalopathy syndrome induced by anti-VEGF agents","volume":"6","author":"Tlemsani","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.lpm.2014.03.028_bib0150","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s10637-010-9406-6","article-title":"Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents","volume":"29","author":"Mir","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.lpm.2014.03.028_bib0155","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10637-010-9458-7","article-title":"Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib","volume":"29","author":"Coriat","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.lpm.2014.03.028_bib0160","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc1305302","article-title":"Pancreatic atrophy: a new late toxicity of sorafenib","volume":"365","author":"Hescot","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0165","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lpm.2014.03.028_bib0175","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0180","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.amjmed.2012.04.026","article-title":"Acute immune-mediated thrombocytopenia triggered by bevacizumab","volume":"125","author":"Dior","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0185","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2006.09.3351","article-title":"Bevacizumab 5mg\/kg can be infused safely over 10minutes","volume":"25","author":"Reidy","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0190","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.dld.2010.10.013","article-title":"Safety of 10min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients","volume":"43","author":"Coriat","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.lpm.2014.03.028_bib0195","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/CAD.0b013e32835cfef1","article-title":"Cervical extravasation of bevacizumab","volume":"24","author":"Dr\u00e9anic","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lpm.2014.03.028_bib0200","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","article-title":"FLT1\u00a0and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?","volume":"8","author":"Fischer","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.lpm.2014.03.028_bib0205","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2013.08.007","article-title":"Drug interactions with solid-tumour targeted therapies","volume":"89","author":"Thomas-Schoemann","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1056\/NEJMc1105083","article-title":"Drug-induced effects on erlotinib metabolism","volume":"365","author":"Mir","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0215","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.yexcr.2008.10.043","article-title":"ERBBs in the gastrointestinal tract: recent progress and new perspectives","volume":"315","author":"Fiske","year":"2009","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.lpm.2014.03.028_bib0220","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1073\/pnas.032678499","article-title":"Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis","volume":"99","author":"Roberts","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2014.03.028_bib0225","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0230","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.critrevonc.2013.05.008","article-title":"Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation","volume":"88","author":"Giampieri","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0235","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0240","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0245","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0250","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0255","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0260","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.03.028_bib0265","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0270","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4\u00a0alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0275","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CCO.0b013e3283474063","article-title":"Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors","volume":"23","author":"Wu","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lpm.2014.03.028_bib0285","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3892\/ol.2013.1301","article-title":"Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: a meta-analysis","volume":"5","author":"Chen","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.lpm.2014.03.028_bib0290","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"25","author":"Soubrane","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.lpm.2014.03.028_bib0295","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/annonc\/mdf254","article-title":"Exacerbation of oxaliplatin neurosensory toxicity following surgery","volume":"13","author":"Gornet","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.lpm.2014.03.028_bib0305","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/annonc\/mdn540","article-title":"Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery","volume":"19","author":"Cacheux","year":"2008","journal-title":"Ann Oncol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214003455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214003455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:28:59Z","timestamp":1565656139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498214003455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0755498214003455"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2014.03.028","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les bioth\u00e9rapies des cancers colorectaux m\u00e9tastatiques en 2014","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2014.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}